Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to assess the effect of obesity on therapeutic response and safety of cyclosporine trough level in nephrotic syndrome patients and calculating a suitable weight-based dose.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• Obese and overweight Nephrotic syndrome adult patients receiving Cyclosporine for more than one month with prednisolone. (BMI>25 kg/m2)

• Normal or underweight individuals Nephrotic syndrome adult patients receiving Cyclosporine for more than one month with prednisolone. (serving as control group)

Exclusion Criteria:

• Hepatic patients liver cirrhosis (moderate to severe liver impairment)

• Cancer patients,

• Pregnant and lactating female patients